NATCO Pharma Limited (NSE:NATCOPHARM)
864.15
+2.05 (0.24%)
Jun 4, 2025, 9:30 AM IST
NATCO Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 44,295 | 39,988 | 27,071 | 19,448 | 20,521 | Upgrade
|
Other Revenue | - | 32 | 14 | 14 | 40 | Upgrade
|
Revenue | 44,295 | 40,020 | 27,085 | 19,462 | 20,561 | Upgrade
|
Revenue Growth (YoY) | 10.68% | 47.76% | 39.17% | -5.34% | 7.37% | Upgrade
|
Cost of Revenue | 6,898 | 7,487 | 6,544 | 5,845 | 5,318 | Upgrade
|
Gross Profit | 37,397 | 32,533 | 20,541 | 13,617 | 15,243 | Upgrade
|
Selling, General & Admin | 5,945 | 5,309 | 4,625 | 4,806 | 4,390 | Upgrade
|
Other Operating Expenses | 9,492 | 9,599 | 6,072 | 5,952 | 4,634 | Upgrade
|
Operating Expenses | 17,789 | 16,827 | 12,443 | 12,383 | 10,310 | Upgrade
|
Operating Income | 19,608 | 15,706 | 8,098 | 1,234 | 4,933 | Upgrade
|
Interest Expense | -239 | -203 | -148 | -132 | -93 | Upgrade
|
Interest & Investment Income | - | 1,013 | 513 | 392 | 566 | Upgrade
|
Currency Exchange Gain (Loss) | - | 103 | 214 | 103 | 40 | Upgrade
|
Other Non Operating Income (Expenses) | 3,545 | 97 | 130 | -3 | 30 | Upgrade
|
EBT Excluding Unusual Items | 22,914 | 16,716 | 8,807 | 1,594 | 5,476 | Upgrade
|
Merger & Restructuring Charges | - | - | -291 | -11 | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | -7 | -52 | 12 | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | -17 | 178 | 427 | 320 | Upgrade
|
Asset Writedown | - | - | -23 | - | - | Upgrade
|
Pretax Income | 22,914 | 16,735 | 8,619 | 2,022 | 5,796 | Upgrade
|
Income Tax Expense | 4,080 | 2,852 | 1,466 | 322 | 1,372 | Upgrade
|
Earnings From Continuing Operations | 18,834 | 13,883 | 7,153 | 1,700 | 4,424 | Upgrade
|
Net Income to Company | 18,834 | 13,883 | 7,153 | 1,700 | 4,424 | Upgrade
|
Minority Interest in Earnings | 20 | - | - | - | -15 | Upgrade
|
Net Income | 18,854 | 13,883 | 7,153 | 1,700 | 4,409 | Upgrade
|
Net Income to Common | 18,854 | 13,883 | 7,153 | 1,700 | 4,409 | Upgrade
|
Net Income Growth | 35.81% | 94.09% | 320.76% | -61.44% | -4.32% | Upgrade
|
Shares Outstanding (Basic) | 179 | 179 | 183 | 182 | 182 | Upgrade
|
Shares Outstanding (Diluted) | 179 | 179 | 183 | 182 | 182 | Upgrade
|
Shares Change (YoY) | -0.21% | -1.67% | 0.08% | -0.04% | 0.02% | Upgrade
|
EPS (Basic) | 105.26 | 77.34 | 39.18 | 9.32 | 24.20 | Upgrade
|
EPS (Diluted) | 105.26 | 77.34 | 39.18 | 9.32 | 24.16 | Upgrade
|
EPS Growth | 36.10% | 97.40% | 320.39% | -61.42% | -4.35% | Upgrade
|
Free Cash Flow | 12,957 | 8,722 | 7,028 | -1,863 | 442 | Upgrade
|
Free Cash Flow Per Share | 72.34 | 48.59 | 38.50 | -10.21 | 2.42 | Upgrade
|
Dividend Per Share | 6.000 | 9.500 | 5.500 | 4.500 | 5.250 | Upgrade
|
Dividend Growth | -36.84% | 72.73% | 22.22% | -14.29% | -22.22% | Upgrade
|
Gross Margin | 84.43% | 81.29% | 75.84% | 69.97% | 74.13% | Upgrade
|
Operating Margin | 44.27% | 39.25% | 29.90% | 6.34% | 23.99% | Upgrade
|
Profit Margin | 42.56% | 34.69% | 26.41% | 8.73% | 21.44% | Upgrade
|
Free Cash Flow Margin | 29.25% | 21.79% | 25.95% | -9.57% | 2.15% | Upgrade
|
EBITDA | 21,960 | 17,506 | 9,669 | 2,600 | 6,066 | Upgrade
|
EBITDA Margin | 49.58% | 43.74% | 35.70% | 13.36% | 29.50% | Upgrade
|
D&A For EBITDA | 2,352 | 1,800 | 1,571 | 1,366 | 1,133 | Upgrade
|
EBIT | 19,608 | 15,706 | 8,098 | 1,234 | 4,933 | Upgrade
|
EBIT Margin | 44.27% | 39.25% | 29.90% | 6.34% | 23.99% | Upgrade
|
Effective Tax Rate | 17.81% | 17.04% | 17.01% | 15.93% | 23.67% | Upgrade
|
Revenue as Reported | 47,840 | 41,269 | 28,117 | 20,438 | 21,557 | Upgrade
|
Advertising Expenses | - | - | - | 326 | 211 | Upgrade
|
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.